FDA-Cleared AI Software Targets Streak Artifacts in Cone-Beam CT
The CleaRecon DL software reportedly removes streak artifacts that can occur with the use of cone-beam computed tomography (CBCT) during interventional radiology procedures.
For interventional radiologists, GE HealthCare has unveiled CleaRecon DL, a deep learning software that addresses the challenge of streak artifacts that can hamper cone-beam computed tomography (CBCT) acquisitions during interventional procedures.
Recently cleared by the Food and Drug Administration (FDA), CleaRecon DL removes streak artifacts from CBCT reconstructed images, according to GE HealthCare.
Designed to remove streak artifacts from reconstructed cone-beam CT images, the FDA-cleared CleaRecon DL software reportedly bolsters image quality for interventional radiology procedures involving the prostate, liver, endovascular aortic repair, and neuroradiology applications, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
Employing deep learning algorithms, the company said CleaRecon DL facilitates improved image clarity during interventional radiology procedures involving the liver and prostate as well as neuroradiology applications and procedures involving endovascular aortic repair.
“The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence,” said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
